Ocuphire Pharma Inc

For the period ended Dec 31, 2023. Filed Mar 8, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 8, 2024

IRD$4.20+0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share amounts and par value)

	As of December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$50,501	$42,634
Accounts receivable	926	1,298
Contract assets and unbilled receivables (Note 9)	1,407	3,552
Prepaids and other current assets	1,099	1,453
Short-term investments	15	49
Total current assets	53,948	48,986
Property and equipment, net	—	6
Total assets	$53,948	$48,992
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$2,153	$1,069
Accrued expenses	1,815	1,684
Derivative liability	74	—
Total current liabilities	4,042	2,753
Total liabilities	4,042	2,753
Commitments and contingencies (Note 3 and Note 7)
Stockholders’ equity:
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022.	—	—
Common stock, par value $0.0001; 75,000,000 shares authorized as of December 31, 2023 and 2022; 23,977,491 and 20,861,315 shares issued and outstanding at December 31, 2023 and 2022, respectively.	2	2
Additional paid-in capital	131,370	117,717
Accumulated deficit	(81,466)	(71,480)
Total stockholders’ equity	49,906	46,239
Total liabilities and stockholders’ equity	$53,948	$48,992

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.